biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > xB3-004

<< Previous

Bullboard Posts

Next >>

Post by JDavenporton Mar 17, 2022 10:43pm

114 Views

Post# 34524060

xB3-004

Bioasis got that preclinical MS study done. That means that in addition to the several agreements signed, Bioasis got one of its own programs, xB3-004, underway. Progranulin soon. (Timing is about right.)

But what happens then with those two? BDs? Or just one to cover them both?

What about xB3-001? My guess is that somebody is working on that, probably has been for a while. Go read DrDR's quotes about these things. She's just aching to spill the beans. But she can't. Partners can be twits about these things, as I have posted for ten years.

But, xB3 is the key. Potential partners can't get through the doors without the key.

Can't wait.

jd